Search

News Benefit of Oral Semaglutide for Patients with Type 2 Diabetes in the General Practitioner's Office

Oral semaglutide is a modern antidiabetic suitable within primary care for people with type 2 diabetes, primarily due to its comprehensive action that includes not only reducing blood glucose and body weight but also a number of other favorable non-glycemic effects.

Source: Modern Treatment of Diabetes with GLP-1 Analogues 22. 5. 2024

News Irritable Bowel Syndrome and Non-specific Inflammatory Bowel Diseases Are Not Evolutionarily Related Diseases

The authors of the presented work attempted to compare the geographical distribution of irritable bowel syndrome and non-specific inflammatory bowel diseases and other factors related to these two diseases to reveal their potential evolutionary connection.

Source: Irritable Bowel Syndrome 19. 6. 2021

News When You Say Amyloid…

The term 'amyloid' was first used by the German doctor Rudolf Virchow in the mid-19th century. He described it as a pathological substance which he originally thought was starch. Although it was quickly discovered that it was a substance of protein nature, the reference to starch (from the Greek amylon) remained in the name.

Source: Amyloidosis 12. 12. 2022

Články časopisu Telemedicine and inflammatory bowel disease –⁠ results of the IBD Assistant pilot project

Author of the article: Malíčková K., Pešinová V., Bortlík M., Ďuricová D., Machková N., Hrubá V., Lukáš M. Jr., Mitrová K., Vašátko M., Kostrejová M., Kolář M., Lukáš M. Source: Gastroenterologie a hepatologie | 1/2020 25. 2. 2020

News Three times on the topic of therapeutic cannabis usage possibilities –⁠ case studies from Czech practice

The following case studies from real Czech practice describe three cases of patients with various diagnoses, indicated for cannabis extract administration. In the first case, there was significant pain relief in an elderly patient with vertebrogenic pain syndrome. The second case study outlines the possibilities of using cannabis extract in the treatment of neuropathic pain in a polymorbid elderly patient. The final contribution describes the effect of this preparation in palliative therapy of an oncological patient.

Source: Medical Cannabis 27. 9. 2023

News Is Dupilumab Effective in AD Therapy for Patients for Whom Cyclosporine A Fails or Cannot Be Given?

Severe forms of atopic dermatitis (AD) may require systemic therapy. However, the immunosuppressant cyclosporine A does not have sufficient efficacy in some patients with AD or is contraindicated for them. Therefore, the phase III clinical trial LIBERTY AD CAFÉ evaluated the efficacy of dupilumab in these patients.

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 3. 3. 2022

News ICIS Report: Potential of TPO-RA as Early Immunomodulatory Treatment of Immune Thrombocytopenia

The report from the meeting of the Intercontinental Cooperative ITP Study Group (ICIS) in 2022 in Lenzerheide, Switzerland, published late last year in the British Journal of Haematology, discusses the potential of early treatment of immune thrombocytopenia with thrombopoietin receptor agonists (TPO-RA) in achieving a disease remission sustainable without further therapy.

Source: Immune Thrombocytopenia 24. 1. 2024

News The Future and Prospects of Type 2 Diabetes Therapy: Can We Fully Cure It with Endoscopy or Genetics?

Diabetes mellitus (DM) cannot be cured, but it can be successfully treated... Will we rewrite this textbook fact passed down for years in the future? Will we be able to completely cure type 2 diabetes mellitus (T2DM) one day? The Prague Institute for Clinical and Experimental Medicine (IKEM) sees endoscopic procedures as one of the promising paths and is preparing to test this groundbreaking method of therapy.

Source: Modern Treatment of Diabetes 6. 5. 2021

News Immunomodulation and Romiplostim −⁠ What Does the Recently Published iROM Study Say?

Primary immune thrombocytopenia (ITP) is caused by an immunity disorder, involving not only the production of antibodies but also changes in cytokine levels, predominance of Th1 lymphocytes over Th2, increase in Th17 cells, and conversely a decrease in T-regulatory lymphocytes (Tregs). One treatment option is the use of thrombopoietin receptor agonists (TPO-RA), which primarily increase platelet production. Recently, attention has also been focused on their potential immunomodulatory effects and protolerogenic effect associated with Tregs activation, which was the subject of the Swiss iROM study.

Source: Immune Thrombocytopenia 24. 1. 2024

News ESC 2022: SGLT2 Inhibitors as Hope for HFpEF: How to Implement Them in Practice?

Patients with heart failure (HF) can significantly benefit from the inclusion of sodium-glucose co-transporter 2 inhibitors (SGLT2i, i.e., gliflozins) in their treatment strategy according to current findings. This also applies to patients with preserved left ventricular ejection fraction (HFpEF). At the ESC 2022 congress, useful information for practical applications was presented in addition to study data. For illustration, we bring a case study from a German practice.

Source: Heart Failure 10. 11. 2022

News Safety of Urgent Initiation of Peritoneal Dialysis

In case of urgent need for kidney function replacement, hemodialysis (HD) with a temporary venous catheter has long been the standard solution. However, it has several disadvantages such as increased mortality or the risk of bacteremia and central venous stenosis. Additionally, multiple procedures are needed to create a permanent venous access. Therefore, there is a growing global interest in urgently initiated peritoneal dialysis (PD), with several clinical studies attesting to its safety, efficacy, and feasibility. However, little has been known about early PD complications and the long-term prognosis of patients in terms of technical and infectious complications.

Source: Chronic Kidney Disease 8. 6. 2021

News Impact of Initial RAAS Inhibitor on Hospitalization Risk in HFrEF Patients

Inhibition of the renin-angiotensin-aldosterone system (RAAS) is considered a key step in the treatment of heart failure with reduced ejection fraction (HFrEF). The preferred medication currently is the angiotensin II receptor and neprilysin inhibitor (ARNI) sacubitril/valsartan, which has shown to improve the prognosis of patients with HFrEF. A recently published study compared the initiation of ARNI or angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) in patients with HFrEF who were not previously treated with a RAAS inhibitor in real-world practice.

Source: Chronic Heart Failure and Lipidology 23. 11. 2022

News Prognostic Significance of the Location of Colorectal Cancer Metastases

An Austrian study presented at the ESMO 2020 conference analyzed the relationship between the localization of colorectal cancer (CRC) metastases and patient survival, the time of metastasis detection, and RAS mutations.

Source: Colorectal Cancer 26. 11. 2021

News Shared Decision-Making on Kidney Function Replacement

Peritoneal dialysis (PD) is not a new development, but its significance is becoming increasingly recognized. Until recently, we may not have fully appreciated its value, but in light of the global threat posed by the current pandemic, its importance is starkly clear. PD is an accessible solution designed for home care and allows patients to avoid visits to healthcare facilities to some extent.

Source: Chronic Kidney Disease 30. 11. 2020

News Shared Decision Making Plays an Important Role in Dialysis

Peritoneal dialysis is very effective and comfortable for patients, yet it is used relatively little in the Czech Republic. Are we giving enough room to patients' preferences?

Source: Chronic Kidney Disease 29. 9. 2020